News of Note—Vetter and Nanoform expand and WuXi Biologics plant gets FDA nod

Financial market data. Image: Pixabay
(Pixabay)

> CDMO Vetter says the expansion of its facility in suburban Chicago is nearly complete. Release

> Vaccine producer Seqirus says for the 2019-2020 flu season, it will manufacture vaccines for all four flu strains recommended by WHO using its cell-based processes. Release 

> China has taken steps to overcome drug shortages in the country including fining some companies for market concentration. Story

> WuXi Biologics announced that its Drug Substance and Drug Product manufacturing facilities at Wuxi city successfully completed a seven-day FDA surveillance inspection by three inspectors for the production of Trogarzo, the first routine GMP inspection since the product's approval. Release

> Helsinki, Finland-based Nanoform says it expects to begin producing drug product this year in a 600 square meter manufacturing plant it is building at Cultivator II in Viikki Life Science Park, Finland. Release

> Adare Pharmaceuticals, has an agreement with Egalet Corporation for technology that enables single-dose formulation of taste-masked, easy-to-swallow oral medications for the pediatric and geriatric populations. Release

> Coquí Radio Pharmaceuticals Corp. has received 206 acres in Oak Ridge, Tennessee, from the Department of Energy on which to build a dedicated medical isotope production facility to address the U.S. reliance on imported medical isotopes that are used for diagnosing and treating a variety of diseases. Release

Read more on

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

CanSino reports positive data for COVID-19 vaccine. Takeda's Alunbrig wins first-line lung cancer nod. GSK inks $231 million deal with Samsung.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.